Nebenwirkungen · Zejula
Zejula 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 33–34
HOS-136906 · Präparat HOS-097936
33 Myelodysplastic syndrome/Acute myeloid leukaemia In clinical studies, MDS/AML occurred in 1% patients treated with Zejula, with 41% of cases having a fatal outcome. The incidence was higher in patients with relapsed ovarian cancer who had received 2 or more lines of prior platinum chemotherapy and with gBRCAmut following 75 months survival follow-up. All patients had potential contributing factors for the development of MDS/AML, having received previous chemotherapy with platinum agents. Many had also received other DNA damaging agents and radiotherapy. The majority of reports were in gBRCAmut carriers. Some patients had a history of previous cancer or of bone marrow suppression.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-10T15:04:00Z · SHA-256 6347b899b1ffe7609d7901f538d2dfbbead89a34d77901643cd1e86915c71a48 · Passage 032325afff5f99454cf785fdf53c929e239ee066e39df1e374f521fe5c735865 · Zeichen 13090–13782 im Abschnitt